A Japan-based pharmaceutical company focused on rare diseases, urology, and specialty therapies, with a growing presence in global orphan drug markets. The firm develops and commercializes treatments including exon-skipping therapies for Duchenne muscular dystrophy, notably viltolarsen (Viltepso), m...
1 member of Congress has disclosed 1 trade in Nippon Shinyaku Co., Ltd. (NPPNY), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2023-02-27 | Daniel Goldman | sell | $1K – $15K |